Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9209781 | 0.93 | NPC1 (0.34) | NPC1POLBRXFP1CYP19A1HTT | |
| SCHEMBL9700566 | 0.87 | HSD11B1 (0.36) | NPC1POLBHTTSMN1; SMN2PARP1 | |
| SCHEMBL9700610 | 0.83 | RXFP1 (0.40) | NPC1POLBRXFP1HTTSMN1; SMN2 | |
| SCHEMBL9699442 | 0.80 | NPC1 (0.34) | NPC1POLBHTTSMN1; SMN2PARP1 | |
| SCHEMBL9206714 | 0.79 | HSD11B1 (0.38) | NPC1POLBHTTSMN1; SMN2PARP1 | |
| SCHEMBL9701782 | 0.78 | POLB (0.39) | NPC1POLBRXFP1HTTSMN1; SMN2 | |
| SCHEMBL9201756 | 0.77 | NPC1 (0.48) | NPC1POLBHTTSMN1; SMN2 | |
| SCHEMBL9738811 | 0.77 | NPC1 (0.35) | NPC1POLBRXFP1CYP19A1HTT | |
| SCHEMBL9216390 | 0.75 | RXFP1 (0.41) | NPC1POLBRXFP1HTTSMN1; SMN2 | |
| SCHEMBL9701851 | 0.75 | TSHR (0.37) | NPC1POLBHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1992015310-A1 | USE OF TRICYCLIC ISOINDOLINONES AS ANTIVIRAL DRUGS, AND NEW, OPTICALLY ACTIVE ISOINDOLINONES | BOEHRINGER MANNHEIM GMBH (DE) | 1992-09-17 | — | — | WO | disclosed |